Answers are grounded in this paper and cite their sources.
Systematic review shows varied cost-effectiveness of COVID-19 options in transplant recipients, suggesting the need for tailored research.
Cost effectiveness varied widely across studies due to differences in variant periods, population risk profiles, model assumptions, and healthcare systems. Future research should integrate variant-specific effectiveness, real-world vaccine responsiveness, long-term COVID-19 outcomes, and adverse events to better inform resource allocation for transplant and other high-risk populations.
No takes yet. Share an insight, caveat, or question.
Grant et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: